兽用皮肤病药物市场－全球产业规模、份额、趋势、机会、预测：按适应症、动物种类、给药途径、分销管道、地区和竞争格局划分，2021-2031年

全球兽医皮肤病药物市场预计将从 2025 年的 179.8 亿美元成长到 2031 年的 312.2 亿美元，复合年增长率为 9.63%。

全球兽用皮肤病药物市场涵盖用于诊断和治疗动物皮肤疾病（例如寄生虫感染疾病、过敏性皮肤炎和自体免疫疾病）的药品和治疗製剂。该行业的主要驱动力是宠物日益人性化以及慢性皮肤病发病率的上升，这两方面都促使宠物饲主寻求更先进的兽医护理并制定长期用药方案。

然而，市场扩张的一大障碍是兽医保健成本的飙升。这一经济壁垒限制了高品质治疗的普及。治疗慢性皮肤病所需的高昂费用常常给家庭预算带来压力，迫使一些饲主推迟甚至放弃必要的治疗。澳洲动物医学协会2025年的报告凸显了这一经济问题，报告指出“12%的宠物饲主在过去一年中需要兽医费用方面的经济援助”，这表明经济限制会阻碍专业皮肤病药物的广泛应用。

市场驱动因素

动物感染疾病、寄生虫感染和过敏性皮肤病的日益增多是全球兽医皮肤病市场的主要驱动力。随着环境过敏原和诱发因素的扩散，异位性皮肤炎等慢性疾病的发生率不断上升，对长期治疗和管理的需求也日益强劲。保险数据也印证了这个趋势。根据 Nationwide 保险公司 2024 年 4 月的分析，异位性皮肤炎或过敏性皮肤炎已连续 12 年成为犬类最常见的疾病，2023 年的保险索赔案例超过 41.5 万例。这表明，迫切需要有效的配方来缓解症状并改善动物福利。

同时，全球宠物饲养量和伴侣动物数量的成长正在扩大动物用药品的基本客群。饲主饲养行为向「拟人化」转变，推动了皮肤病专科医疗保健支出的增加。根据欧洲宠物食品工业联合会（FEDIAF）于2024年6月发布的《2024年事实与数据》报告，欧洲约有1.66亿户家庭至少拥有一隻宠物，代表着一个巨大的潜在市场。宠物饲养量和支出的成长反映在强劲的企业业绩上；例如，硕腾公司（Zoetis）2024年第三季皮肤病业务收入达4.49亿美元，充分体现了这些因素的显着商业性影响。

市场挑战

兽医保健成本的不断上涨是全球兽医皮肤病药物市场成长的主要障碍。随着诊断和长期用药费用的增加，宠物饲主面临经济负担，难以获得高品质的皮肤病治疗。这种经济上的困难导致许多家庭推迟就医或放弃治疗慢性疾病（例如过敏性皮肤炎）所需的药物，直接减少了处方笺数量。因此，经济压力抑制了需求，往往超过了人们治疗那些被认为不危及生命的疾病的意愿。

市场萎缩的趋势得到了产业数据的佐证，数据显示，经济负担导致消费者支出改变。美国兽医学会（AVMA）报告称，2024年“兽医总支出年减4%”，这表明价格上涨正促使饲主减少对专业服务的使用。支出下降清楚地表明，成本压力正在缩小专业皮肤病产品的基本客群，并阻碍该行业的扩张潜力。

市场趋势

Janus激酶（JAK）抑制剂适应症的不断扩大，正在改变该领域的竞争格局，使其从垄断转变为多产品治疗层级。传统的异位性皮肤炎治疗仅限于单一主流製剂，但近期监管部门的核准引入了新的JAK抑制剂，使兽医能够根据不同的安全性特征和给药方案来选择治疗犬瘙痒的药物。这种多样性使兽医能够制定个人化的治疗方案，从而促进了这些药物在临床实践中的快速普及。例如，礼来公司（Elanco）在2025年5月报告称，其新型皮肤病治疗药物Zenrelia已在美国约11,000家动物医院使用，凸显了这些口服药物的快速商业性成功。

同时，非抗生素酶製剂的兴起正成为全球抗生素抗药性挑战的关键倡议。为了减少对全身性抗生素治疗皮肤感染疾病的依赖，製造商正在开发先进的局部用药方案，例如生物黏附凝胶和药用洗髮精，这些方案利用脂质和酵素来修復皮肤屏障并控制微生物生长。这种向多方面、非全身性治疗方法的转变正在推动专注于皮肤卫生领域的公司发展。在2025年1月的新闻稿中，Verbach宣布其伴侣动物部门经外汇调整后成长了10.7%，这一业绩主要归功于公司专业皮肤科产品线的强劲销售。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球兽医皮肤病市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 适应症（寄生虫感染疾病、性行为感染、其他）
  • 动物种类（伴侣动物、家畜）
  • 给药途径（外用、口服、注射）
  • 分销管道（医院和药房、零售、电子商务）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美兽医皮肤病市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲兽用皮肤病药物市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区兽用皮肤病药物市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲兽用皮肤病药物市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美兽用皮肤病药物市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球兽用皮肤病药物市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale SA
• Boehringer Ingelheim International GmbH
• VETOQUINOL SA
• Bioiberica SAU
• Bimeda Inc.
• Virbac SA
• Vivaldis

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Veterinary Dermatology Drugs Market to increase from USD 17.98 Billion in 2025 to USD 31.22 Billion by 2031, with a CAGR of 9.63%. The Global Veterinary Dermatology Drugs Market comprises pharmaceutical agents and therapeutic formulations designed for diagnosing and managing animal skin disorders, such as parasitic infections, allergic dermatitis, and autoimmune conditions. This sector is primarily propelled by the growing trend of pet humanization and the increasing incidence of chronic dermatological diseases, both of which encourage pet owners to pursue advanced veterinary care and commit to long-term medication plans.

However, market expansion faces a significant obstacle in the form of rising veterinary healthcare costs, which establish financial barriers and restrict access to premium treatments. The substantial expense required to manage chronic skin conditions often strains household finances, compelling some owners to postpone or skip essential care. This affordability issue is highlighted by 'Animal Medicines Australia', which noted in '2025' that '12% of pet owners needed financial help for veterinary care in the past year', indicating that economic constraints may limit the wider adoption of specialized dermatology drugs.

Market Driver

The escalating prevalence of infectious, parasitic, and allergic skin diseases in animals acts as a major driver for the Global Veterinary Dermatology Drugs Market. As environmental allergens and triggers become more widespread, the occurrence of chronic conditions like atopic dermatitis has risen, creating a strong demand for long-term therapeutic management. Insurance data confirms this trend; according to Nationwide's April 2024 analysis, atopic or allergic dermatitis was the leading medical condition for dogs for the twelfth year in a row, with over 410,500 claims filed in 2023, demonstrating the urgent need for effective formulations to alleviate symptoms and enhance animal welfare.

Simultaneously, the global increase in pet ownership and the companion animal population is broadening the customer base for veterinary pharmaceuticals. The shift in owner behavior toward pet humanization has resulted in a higher willingness to spend on specialized healthcare for skin ailments. A June 2024 report by FEDIAF EuropeanPetFood titled 'Facts & Figures 2024' indicates that about 166 million European households own at least one pet, representing a massive addressable market. This growing ownership and expenditure are reflected in strong corporate results, such as Zoetis reporting $449 million in revenue from its dermatology franchise in the third quarter of 2024, illustrating the substantial commercial impact of these factors.

Market Challenge

Rising veterinary healthcare costs pose a significant barrier to the growth of the Global Veterinary Dermatology Drugs Market. As the prices for diagnostics and long-term pharmaceutical management increase, pet owners encounter financial hurdles that limit their access to premium dermatological therapies. This affordability crisis leads many households to delay professional consultations or forgo necessary medications for chronic issues like allergic dermatitis, directly reducing prescription volumes. Consequently, demand is suppressed as economic pressures override the desire to treat conditions that are often perceived as non-life-threatening.

This market contraction is supported by industry data indicating a shift in consumer spending due to economic strain. The 'American Veterinary Medical Association' reported in '2024' that 'overall veterinary spending decreased by 4% compared to the previous year', suggesting that higher prices are forcing owners to cut back on professional services. This decline in expenditure demonstrates how cost pressures are effectively shrinking the customer base for specialized dermatology drugs, thereby hindering the sector's potential for wider expansion.

Market Trends

The expansion of Janus Kinase (JAK) inhibitor applications is transforming the sector's competitive landscape from a monopoly into a multi-product therapeutic class. While earlier treatments for atopic dermatitis were restricted to a single dominant formulation, recent regulatory approvals have introduced new JAK inhibitors that provide veterinarians with alternative safety profiles and dosing regimens for managing canine pruritus. This variety enables practitioners to customize treatment plans, leading to rapid adoption in general practice; for example, Elanco reported in May 2025 that its new dermatology treatment, Zenrelia, had been adopted by roughly 11,000 U.S. veterinary clinics, highlighting the swift commercial success of these oral therapeutics.

In parallel, the rise of non-antibiotic enzymatic topicals is becoming a key response to the global issue of antimicrobial resistance. To decrease reliance on systemic antibiotics for skin infections, manufacturers are developing advanced topical solutions, such as bio-adhesive gels and medicated shampoos, which use lipids and enzymes to restore the skin barrier and control microbial growth. This shift toward multimodal, non-systemic management is driving growth for companies specializing in dermatological hygiene; Virbac's January 2025 press release noted a 10.7% growth in its companion animal division at constant exchange rates, a performance largely attributed to the strong sales of its specialized dermatology line.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale S.A.
• Boehringer Ingelheim International GmbH
• VETOQUINOL S.A.
• Bioiberica S.A.U.
• Bimeda Inc.
• Virbac S.A.
• Vivaldis

Report Scope

In this report, the Global Veterinary Dermatology Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Veterinary Dermatology Drugs Market, By Indication

• Parasitic Infections
• Allergic Infections
• Others

Veterinary Dermatology Drugs Market, By Animal Type

• Companion Animals
• Livestock Animals

Veterinary Dermatology Drugs Market, By Route of Administration

• Topical
• Oral
• Injectable

Veterinary Dermatology Drugs Market, By Distribution Channel

• Hospital Pharmacies
• Retail
• E-commerce

Veterinary Dermatology Drugs Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Veterinary Dermatology Drugs Market.

Available Customizations:

Global Veterinary Dermatology Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Veterinary Dermatology Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Parasitic Infections, Allergic Infections, Others)
  • 5.2.2. By Animal Type (Companion Animals, Livestock Animals)
  • 5.2.3. By Route of Administration (Topical, Oral, Injectable)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail, E-commerce)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Veterinary Dermatology Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Veterinary Dermatology Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Veterinary Dermatology Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Veterinary Dermatology Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Veterinary Dermatology Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Veterinary Dermatology Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Veterinary Dermatology Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Veterinary Dermatology Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Veterinary Dermatology Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Veterinary Dermatology Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Veterinary Dermatology Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Veterinary Dermatology Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Veterinary Dermatology Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Veterinary Dermatology Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Veterinary Dermatology Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Veterinary Dermatology Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Veterinary Dermatology Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Veterinary Dermatology Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Veterinary Dermatology Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Veterinary Dermatology Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Veterinary Dermatology Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Veterinary Dermatology Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Veterinary Dermatology Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Veterinary Dermatology Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Veterinary Dermatology Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Elanco Animal Health Inc.
• 15.4. Ceva Sante Animale S.A.
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. VETOQUINOL S.A.
• 15.7. Bioiberica S.A.U.
• 15.8. Bimeda Inc.
• 15.9. Virbac S.A.
• 15.10. Vivaldis

16. Strategic Recommendations

17. About Us & Disclaimer